Drug Trial Radar · NCT05016882
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
698
Actual
Start
Aug 31, 2021
Primary completion
Dec 17, 2024
Study completion Mar 14, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Aug 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH). NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own. The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH. Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of the medicines and a placebo OR 2 placebo injections. Which treatment participants get is decided by chance. A placebo is a dummy medicine which looks like the real medicine but doesn't contain any active medicine. The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone calls with the study doctor. Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start (if participants have not had a biopsy recently) and one at the end of the study treatment. Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
Conditions
- Non-alcoholic Steatohepatitis
Interventions
NNC0194 0499 50 mg/mLDrug
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months
Placebo (NNC0194-0499)Drug
Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months
Semaglutide 3 mg/mLDrug
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months
Semaglutide placeboDrug
Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months
NNC0174 0833 10 mg/mLDrug
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months
NNC0174 0833 placeboDrug
Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in liver fibrosis and no worsening of NASH (Yes/No)Time frame: From baseline (week 0) to week 52
Locations
255 sites in 24 countries. Site status is shown where the registry gives one.
North AL Health Res, LLC
Huntsville, Alabama
The Institute for Liver Health
Chandler, Arizona
Inst-Liver Hlth dba AZ Liver H
Peoria, Arizona
Del Sol Research Management, LLC
Tucson, Arizona
Hope Clinical Research
Canoga Park, California
UCSD NAFLD Research Center
La Jolla, California
OM Research LLC
Lancaster, California
Digestive Hlth Res of SoCa
Long Beach, California
Stanford Medicine
Redwood City, California
UC Davis Hlth -Midtwn Ambu Cen
Sacramento, California
Peak Gastro Assoc-Col Springs
Colorado Springs, Colorado
Hartford Hsptl_Hartford
Hartford, Connecticut
Integrity Clinical Research, LLC
Doral, Florida
Miguel Rebollar PA
Hialeah, Florida
Nature Coast Clinical Research_Inverness
Inverness, Florida
UF Hlth Jacksonville
Jacksonville, Florida
Florida Research Institute, LLC
Lakewood Rch, Florida
ClinCloud,LLC
Maitland, Florida
Optimus U, Corp
Miami, Florida
Univ of Miami/Schiff Ctr
Miami, Florida
Covenant Metabolic Specialists LLC
University Park, Florida
ClinCloud, LLC
Viera E., Florida
Florida Medical Clinic Orlando Health
Zephyrhills, Florida
Florida Medical Clinic, LLC
Zephyrhills, Florida
Piedmont Healthcare
Atlanta, Georgia
Digestive Healthcare of Georgia
Atlanta, Georgia
Gastroenterology Assoc_ CGA
Macon, Georgia
Gastroint Spec of Georgia
Marietta, Georgia
EBGS Clinical Research Center, LLC
Snellville, Georgia
Grand Teton Gastroenterology
Idaho Falls, Idaho
Digestive Research Alliance of Michiana
South Bend, Indiana
University Of Kansas Hospital
Kansas City, Kansas
Kansas Medical Clinic, PA
Topeka, Kansas
Tandem Clinical Research - Houma
Houma, Louisiana
Tandem Clinical Research
Marrero, Louisiana
Tandem Clinical Research - Metairie
Metairie, Louisiana
Louisiana Research Center, LLC
Shreveport, Louisiana
Mercy Medical Center, GI Research
Baltimore, Maryland
Walter Reed Nat Mil Md Ctr
Bethesda, Maryland
Henry Ford Hospital_Detroit
Detroit, Michigan
Showing 40 of 255 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.